All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs

November 3rd 2025

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Roswell Park Care Network Expands to Albany in Collaboration with St. Peter’s Health Partners

November 3rd 2025

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.

Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma

November 3rd 2025

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

Lifileucel Displays Antitumor Activity in Advanced Nonsquamous NSCLC

November 3rd 2025

Lifileucel was deemed safe and active in patients with previously treated, advanced nonsquamous NSCLC without certain actionable genetic mutations.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Evolving Role of TKIs and Antibody-Based Strategies Refines Ph-Positive ALL Management

November 3rd 2025

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

FDA Approval of Zongertinib Marks a Targeted Advancement for Patients With HER2-Mutant NSCLC

November 3rd 2025

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

New ADC Data Underscore Progress and Highlight Challenges in HER2+ Breast Cancer and TNBC Management

November 2nd 2025

In a recent Peer Exchange, breast cancer experts discussed updates from ESMO 2025, including practice-informing data with antibody-drug conjugates.

The OncFive: Top Oncology Articles for the Week of 10/26

November 1st 2025

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Revisit Every OncLive On Air Episode From October 2025

November 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in October 2025.

Concerns Escalate About the Fundamental Integrity of Scientific Peer-Reviewed Literature

October 31st 2025

Federal Funding Cuts Hit Cancer Research Despite Public Support

October 31st 2025

Primo Nery Lara, Jr., MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Personalized, Patient-Centered Strategies Shape the Evolving Management of Metastatic Pancreatic Cancer

October 31st 2025

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Mayo Clinic Discovery of Breast Cancer Treatment Resistance Can Lead to New Hope for Some

October 31st 2025

Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some patients.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2025 Luminary Awards in GI Cancer

October 30th 2025

OncLive® and the Ruesch Center at Georgetown Lombardi announce the 2025 Luminary Award winners in gastrointestinal cancers.